FTC Release: FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets

Dow Jones
08/21

The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel--a drug used to treat rheumatoid arthritis and other inflammatory conditions--allowing Amgen to extend its monopoly over the biologic drug.

View Press Release: https://www.ftc.gov/news-events/news/press-releases/2026/08/ftc-files-amicus-brief-protect-competition-biologic-drug-markets

 

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10